Introduction
Materials and methods
Study population
ECRIC | WMCIU | |||
---|---|---|---|---|
Total Number of Subjects | 5,694 | 5,468 | ||
Total time at risk (years) | 31,904 | 25,917 | ||
Median follow-up (years)* | 5.65 | (0.04 to 8.00)† | 4.85 | (0.07 to 8.00)† |
Number of breast cancer deaths | 737 | 668 | ||
Number of other deaths | 338 | 287 | ||
Annual breast cancer mortality rate | 0.023 | (0.021 to 0.025)‡ | 0.026 | (0.024 to 0.028)‡ |
Five-year breast cancer survival rate | 0.89 | (0.88 to 0.90)‡ | 0.88 | (0.87 to 0.89)‡ |
Median age at diagnosis, years | 58 | (23 to 95)† | 58 | (22 to 93)† |
Number | Number | |||
Age, years | ||||
<35 | 111 | 2 | 108 | 2 |
35 to 49 | 1,172 | 21 | 1,195 | 22 |
50 to 64 | 2,630 | 46 | 2,393 | 44 |
65 to 74 | 1,124 | 20 | 1,101 | 20 |
75+ | 657 | 12 | 671 | 12 |
Nodal status | ||||
0 | 3,532 | 62 | 3,184 | 58 |
1 | 741 | 13 | 746 | 14 |
2 to 4 | 806 | 14 | 792 | 14 |
5 to 9 | 380 | 7 | 451 | 8 |
10+ | 235 | 4 | 295 | 5 |
Tumour size, mm | ||||
<10 | 625 | 11 | 485 | 9 |
10 to 19 | 2,310 | 41 | 2,136 | 39 |
20 to 29 | 1,627 | 29 | 1,566 | 29 |
30 to 49 | 845 | 15 | 923 | 17 |
50+ | 287 | 5 | 358 | 7 |
Grade | ||||
I | 1,005 | 18 | 1,017 | 19 |
II | 2,927 | 51 | 2,442 | 45 |
III | 1,762 | 31 | 2,009 | 37 |
Oestrogen Receptor (ER) Status | ||||
ER negative | 991 | 17 | 1,116 | 20 |
ER positive | 4,703 | 83 | 4,352 | 80 |
Adjuvant therapy | ||||
Chemotherapy | 1,905 | 33 | 2,121 | 39 |
Endocrine therapy | 4,268 | 75 | 2,406 | 44 |
Combined chemoendocrine | 1,122 | 20 | 579 | 11 |
Screen detected | ||||
Yes | 1,621 | 28 | 1,256 | 23 |
No | 4,073 | 72 | 4,212 | 77 |
Prognostic model parameters
Model discrimination and calibration
Results
Initial model fit
ER Positive Model | ER Negative Model | |||||||
---|---|---|---|---|---|---|---|---|
Prognostic Factor | Hazard ratio | 95% CI | Coefficient | SE | Hazard ratio | 95% CI | Coefficient | SE |
Number Positive Nodes* | ||||||||
(0, 1, 2 to 4, 5 to 9, 10+) | 1.75 | 1.62 to 1.89 | 0.56 | 0.04 | 1.55 | 1.44 to 1.68 | 0.44 | 0.04 |
Tumour Size, mm* | ||||||||
(<10, 10 to 19, 20 to 29, 30 to 49, 50+) | 1.43 | 1.30 to 1.58 | 0.36 | 0.05 | 1.45 | 1.29 to 1.63 | 0.37 | 0.06 |
Tumour Grade* | 1.43 | 1.30 to 1.58 | 0.36 | 0.05 | 1.45 | 1.29 to 1.63 | 0.37 | 0.06 |
(Low, Intermediate, High) | 1.43 | 1.30 to 1.58 | 0.36 | 0.05 | 1.45 | 1.29 to 1.63 | 0.37 | 0.06 |
Detection by Screening | 0.70 | 0.53 to 0.92 | -0.36 | 0.14 | 0.86 | 0.56 to 1.32 | -0.15 | 0.22 |
Chemotherapy | 0.73 | 0.60 to 0.89 | -0.31 | 0.1 | 0.82 | 0.62 to 1.08 | -0.2 | 0.14 |
Hormone therapy | 0.95 | 0.74 to 1.23 | -0.05 | 0.13 | 1.43 | 1.09 to 1.89 | 0.36 | 0.14 |
Year 5 deaths* | Year 8 deaths* | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Group | N | % | A | P† | Mortality Difference | A | P† | Mortality Difference | AUC | SE |
Total | 5,694 | 100.00 | 841 | 890 | 0.86 | 1,075 | 1,082 | 0.12 | 0.81 | 0.007 |
Age, years | ||||||||||
<35 | 111 | 1.95 | 28 | 23 | 4.5 | 31 | 27 | 3.6 | 0.83 | 0.044 |
35 to 49 | 1,172 | 20.58 | 150 | 171 | 1.79 | 187 | 209 | 1.88 | 0.81 | 0.017 |
50 to 64 | 2,630 | 46.19 | 270 | 289 | 0.72 | 354 | 359 | 0.19 | 0.80 | 0.013 |
65 to 74 | 1,124 | 19.74 | 176 | 191 | 1.33 | 227 | 233 | 0.53 | 0.79 | 0.019 |
75+ | 657 | 11.54 | 217 | 216 | 0.15 | 276 | 254 | 3.35 | 0.68 | 0.021 |
Nodal status | ||||||||||
Negative | 3,532 | 62.03 | 297 | 350 | 1.5 | 408 | 433 | 0.71 | 0.76 | 0.013 |
Positive | 2,162 | 37.97 | 544 | 541 | 0.14 | 667 | 649 | 0.83 | 0.80 | 0.010 |
Tumour size, mm | ||||||||||
<10 | 625 | 10.98 | 30 | 39 | 1.44 | 41 | 49 | 1.28 | 0.75 | 0.038 |
10 to 19 | 2,310 | 40.57 | 194 | 222 | 1.21 | 267 | 280 | 0.56 | 0.75 | 0.017 |
20 to 29 | 1,627 | 28.57 | 277 | 283 | 0.37 | 363 | 347 | 0.98 | 0.79 | 0.013 |
30 to 49 | 845 | 14.84 | 215 | 226 | 1.3 | 259 | 270 | 1.3 | 0.76 | 0.018 |
50+ | 287 | 5.04 | 125 | 119 | 2.09 | 145 | 136 | 3.14 | 0.82 | 0.024 |
Grade | ||||||||||
I | 1,005 | 17.65 | 38 | 64 | 2.59 | 55 | 82 | 2.69 | 0.76 | 0.035 |
II | 2,927 | 51.40 | 331 | 357 | 0.89 | 455 | 445 | 0.34 | 0.77 | 0.013 |
III | 1,762 | 30.94 | 472 | 470 | 0.11 | 565 | 555 | 0.57 | 0.77 | 0.012 |
Oestrogen Receptor (ER) Status | ||||||||||
Negative | 991 | 17.40 | 321 | 318 | 0.3 | 364 | 353 | 1.11 | 0.77 | 0.016 |
Positive | 4,703 | 82.60 | 520 | 572 | 1.11 | 711 | 729 | 0.38 | 0.80 | 0.009 |
Validation
Year 5 deaths* | Year 8 deaths* | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Group | N | % | A | P† | Mortality Difference | A | P† | Mortality Difference | AUC | SE |
Total | 5,468 | 100 | 862 | 950 | 1.61 | 955 | 1006 | 0.93 | 0.79 | 0.008 |
Age, years | ||||||||||
<35 | 108 | 1.98 | 21 | 24 | 2.78 | 28 | 26 | 1.85 | 0.70 | 0.057 |
35 to 49 | 1,195 | 21.85 | 153 | 185 | 2.68 | 175 | 201 | 2.18 | 0.79 | 0.018 |
50 to 64 | 2,393 | 43.76 | 279 | 311 | 1.34 | 310 | 334 | 1 | 0.80 | 0.013 |
65 to 74 | 1,101 | 20.14 | 198 | 203 | 0.45 | 218 | 217 | 0.09 | 0.76 | 0.018 |
75+ | 671 | 12.27 | 211 | 216 | 0.75 | 224 | 228 | 0.6 | 0.72 | 0.021 |
Nodal status | ||||||||||
Negative | 3,184 | 58.23 | 265 | 333 | 2.14 | 301 | 357 | 1.76 | 0.74 | 0.015 |
Positive | 2,284 | 41.77 | 597 | 606 | 0.39 | 654 | 648 | 0.26 | 0.75 | 0.011 |
Tumour size, mm | ||||||||||
<10 | 485 | 8.87 | 27 | 32 | 1.03 | 29 | 34 | 1.03 | 0.82 | 0.040 |
10 to 19 | 2,136 | 39.06 | 173 | 216 | 2.01 | 196 | 233 | 1.73 | 0.76 | 0.018 |
20 to 29 | 1,566 | 28.64 | 259 | 274 | 0.96 | 286 | 295 | 0.57 | 0.71 | 0.017 |
30 to 49 | 923 | 16.88 | 257 | 258 | 0.11 | 272 | 276 | 0.43 | 0.72 | 0.018 |
50+ | 358 | 6.55 | 146 | 160 | 3.91 | 156 | 168 | 3.35 | 0.72 | 0.027 |
Grade | ||||||||||
I | 1,017 | 18.6 | 66 | 67 | 0.1 | 75 | 72 | 0.29 | 0.79 | 0.029 |
II | 2,442 | 44.66 | 314 | 318 | 0.16 | 359 | 344 | 0.61 | 0.77 | 0.013 |
III | 2,009 | 36.74 | 482 | 554 | 3.58 | 521 | 589 | 3.38 | 0.75 | 0.012 |
Oestrogen Receptor (ER) Status | ||||||||||
Negative | 1,116 | 20.41 | 317 | 364 | 4.21 | 341 | 380 | 3.49 | 0.76 | 0.016 |
Positive | 4,352 | 79.59 | 545 | 575 | 0.69 | 614 | 625 | 0.25 | 0.78 | 0.010 |
Summary comparison of overview vs. model-derived therapy benefit estimates
All cause mortality | Breast specific mortality | Person-Years Lost | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
ECRIC Model: | Hormone coefficient | Chemotherapy coefficient | A | P | ROC | A | P | ROC | Total Possible PY‡ | A | P |
Full | Model | Model | 1,075 | 1,082 | 0.81 | 737 | 768 | 0.84 | 35,003 | 3,099 | 3,341 |
Full | Overview* | Overview | 1,075 | 984 | 0.81 | 737 | 660 | 0.83 | 35,003 | 3,099 | 3,030 |
Constrained | Model† | Model | 1,075 | 980 | 0.81 | 737 | 656 | 0.83 | 35,003 | 3,099 | 3,061 |
Constrained | Overview | Overview | 1,075 | 990 | 0.81 | 737 | 667 | 0.83 | 35,003 | 3,099 | 3,089 |
WMCIU
Model: | |||||||||||
Full | Model | Model | 955 | 1,006 | 0.79 | 668 | 743 | 0.82 | 28,322 | 2,405 | 2,513 |
Full | Overview | Overview | 955 | 956 | 0.79 | 668 | 690 | 0.81 | 28,322 | 2,405 | 2,376 |
Constrained | Model† | Model | 955 | 952 | 0.78 | 668 | 685 | 0.81 | 28,322 | 2,405 | 2,406 |
Constrained | Overview | Overview | 955 | 965 | 0.78 | 668 | 699 | 0.81 | 28,322 | 2,405 | 2,436 |